Parkinson disease

Last updated: April 20, 2026

Parkinson disease

Firdus

Firdus

Nasal cavity and larynx histology
Pediatric upper airway conditions: Clinical
Nasal, oral and pharyngeal diseases: Pathology review
Pediatric ear, nose, and throat conditions: Clinical
Tympanic membrane perforation
Warthin tumor
Dizziness and vertigo: Clinical
Vertigo: Pathology review
Neck trauma: Clinical
Eye conditions: Retinal disorders: Pathology review
Eye conditions: Refractive errors, lens disorders and glaucoma: Pathology review
Eye conditions: Inflammation, infections and trauma: Pathology review
Premature rupture of membranes: Clinical
Pregnancy
Abdominal pain: Clinical
Virilization: Clinical
Sexually transmitted infections: Clinical
Contraception: Clinical
Vulvar cancer: Clinical
Urinary incontinence: Pathology review
Vulvovaginitis: Clinical
Vaginal cancer: Clinical
Infertility: Clinical
Cervical cancer: Clinical
Uterine stimulants and relaxants
Menstrual cycle
Endometritis
Preeclampsia & eclampsia
Gestational diabetes
Gestational hypertension
Placenta accreta
Preterm labor
Uterine disorders: Pathology review
Ovarian cysts and tumors: Pathology review
Cervical cancer: Pathology review
Vaginal and vulvar disorders: Pathology review
Complications during pregnancy: Pathology review
Pediatric gastrointestinal bleeding: Clinical
Pediatric infectious rashes: Clinical
Pediatric brain tumors
Pediatric brain tumors: Pathology review
Pediatric vomiting: Clinical
Congenital heart defects: Clinical
Congenital pulmonary airway malformation
Congenital gastrointestinal disorders: Pathology review
Congenital neurological disorders: Pathology review
Pediatric urological conditions: Clinical
Dandy-Walker malformation
Congenital adrenal hyperplasia: Clinical
Beta-thalassemia
Neonatal jaundice: Clinical
Anaphylaxis
Food allergies and EpiPens: Information for patients and families (The Primary School)
Pediatric allergies: Clinical
Food allergy
Vaccinations: Clinical
Allergic rhinitis
Pediatric lower airway conditions: Clinical
Pediatric upper airway conditions: Clinical
Pediatric bone tumors: Clinical
Pediatric ophthalmological conditions: Clinical
Constitutional growth delay
Growth and development
Growth hormone deficiency
Delayed puberty
Precocious and delayed puberty: Clinical
Hemophilia
Coagulation disorders: Pathology review
Bleeding disorders: Clinical
Osteomalacia and rickets
Achondroplasia
Asthma
Asthma: Clinical
Asthma: Information for patients and families (The Primary School)
Sleep apnea
Nasal polyps
Tracheoesophageal fistula
Anal fistula
Neuromuscular junction disorders: Pathology review
Muscular dystrophy
Muscular dystrophies and mitochondrial myopathies: Pathology review
Carpal tunnel syndrome
Erb-Duchenne palsy
Klumpke paralysis
Compartment syndrome
Sciatica
Achondroplasia
Osteomyelitis
Paget disease of bone
Sjogren syndrome
Systemic lupus erythematosus
Antiphospholipid syndrome
Raynaud phenomenon
Polymyositis
Dermatomyositis
Polymyalgia rheumatica
Lambert-Eaton myasthenic syndrome
Myasthenia gravis
Fibromyalgia
Septic arthritis
Rheumatoid arthritis
Gout
Osteoarthritis
Psoriatic arthritis
Ankylosing spondylitis
Reactive arthritis
Pheochromocytoma
Dementia and delirium: Clinical
Medication overdoses and toxicities: Pathology review
Drug misuse, intoxication and withdrawal: Hallucinogens: Pathology review
Drug misuse, intoxication and withdrawal: Stimulants: Pathology review
Drug misuse, intoxication and withdrawal: Other depressants: Pathology review
Drug misuse, intoxication and withdrawal: Alcohol: Pathology review
Dissociative disorders: Clinical
Anxiety disorders: Clinical
Somatic symptom disorders: Clinical
Toxidromes: Clinical
Perinatal infections: Clinical
Congenital TORCH infections: Pathology review
Kawasaki disease: Clinical
Developmental milestones: Clinical
Sickle cell disease: Clinical
Pediatric bone and joint infections: Clinical
Skin and soft tissue infections: Clinical
Viral exanthems of childhood: Pathology review
Elimination disorders: Clinical
Neurodevelopmental disorders: Clinical
Cystic fibrosis: Clinical
Pediatric orthopedic conditions: Clinical
Migraine medications
Osteoporosis medications
Benign breast conditions: Pathology review
Multiple sclerosis
Meningitis
Intracerebral hemorrhage
Subarachnoid hemorrhage
Parkinson disease
Guillain-Barre syndrome
Seronegative arthritis: Clinical
Scleroderma: Pathology review
Scleroderma
Yellow fever virus
Zika virus
Ovarian germ cell tumors
Ovarian cysts, cancer, and other adnexal masses: Clinical
Ovarian cyst
Ascending and descending spinal tracts
Muscle weakness: Clinical

Transcript

Watch video only

Parkinson disease, named after Doctor James Parkinson, who first described it, is a progressive neurodegenerative condition characterized by the gradual loss of dopamine-producing neurons in a brain region called the substantia nigra.

Long before the time of Doctor Parkinson, signs of this condition appeared in ancient tales. In Homer’s Odyssey, King Nestor, once a fierce and fearless warrior, slowly changed with age. His hands started to tremble, his steps became sluggish, and his body became stiff, so he could no longer join the battle. His story sounds all too familiar to what we today recognize as Parkinson disease.

Now, to understand what was going on with King Nestor, we need to look deep within the brain, specifically at the basal ganglia. The basal ganglia play a major role in carrying out learned motor plans, such as riding a bike to university. Moreover, they help fine-tune and shape movement while also controlling unwanted or unnecessary motor activity. Basal ganglia do this by modulating signals from the motor part of the thalamus to the motor cortex. Once those signals reach the motor cortex, they travel down the spinal cord to activate muscles, so you can spin those wheels and make it to pathology class on time. At the same time, basal ganglia help regulate muscle tone and help maintain posture.

The basal ganglia include the striatum, which consists of the caudate nucleus and putamen; the globus pallidus; the subthalamic nucleus; and the substantia nigra. When it comes to Parkinson disease, the most important player is the substantia nigra. This phrase literally means black substance and originates from its dark appearance, which comes from melanin-rich neurons. You can picture it as a strong shot of espresso tucked into your midbrain, small, dark, and packed with power.

Now, the substantia nigra consists of two parts. The pars reticulata receives signals from the striatum and sends them down to the thalamus, using the inhibitory, calming neurotransmitter GABA. This helps keep your movements steady and prevents unwanted motions from slipping through. On the other hand, the pars compacta contain dopamine-producing neurons that project to the striatum. This connection forms the nigrostriatal pathway, which supplies the striatum with dopamine and helps initiate movement. Without enough dopamine flowing through it, even simple actions, like reaching for your favorite chocolate bar, can become difficult.

In Parkinson disease, the dopamine-producing neurons in the pars compacta slowly die off. As the brain loses more of these neurons over time, it sends weaker signals through the nigrostriatal pathway, which impairs the initiation and control of voluntary movements.

While most of the time, the underlying cause is unknown, we know that several genetic mutations are associated with Parkinson disease. Based on the type of mutation, we can classify Parkinson disease into autosomal dominant and autosomal recessive types.

Autosomal dominant types are associated with mutations in the SCNA gene, which encodes alpha-synuclein that enables neurons to communicate with each other. When the SCNA gene mutates, the cell produces abnormal alpha-synuclein that misfolds and accumulates within neurons, eventually forming Lewy bodies. These round, eosinophilic structures are the hallmark of Parkinson disease. Next, there’s the LRRK2 gene, which encodes leucine-rich repeat kinase 2, an enzyme that's important with intracellular signaling. When this gene mutates, the enzyme stops working, causing various cellular functions to malfunction.

On the flip side, in the autosomal recessive types, we have mutations of the PARK7 gene, which encodes DJ-1 protein; PINK1 gene, which encodes PINK1 protein; and PARK2 gene, which encodes Parkin protein. These proteins are essential for normal mitochondria functioning. When these proteins don’t work as they should, mitochondrial dysfunction sets in, eventually leading to cell damage and death.

It’s also important to remember that some people with Parkinson disease carry mutations in the GBA1 gene. This gene makes an enzyme called glucocerebrosidase, which helps lysosomes break down and clear out cellular waste. When the enzyme doesn’t work properly, cellular waste accumulates, disrupting normal cell processes and eventually causing cell death. These same mutations are known to cause a lysosomal storage disorder called Gaucher disease. However, we are still not sure how this mutation increases the risk of Parkinson disease.

Regardless of the underlying genetic mutation and type, the loss of melanin-rich neurons causes substantia nigra to look much paler than usual. It’s like pouring milk into that cup of espresso tucked in the brain.

As dopamine-producing neurons die off, dopamine levels in the nigrostriatal pathway gradually decline. With less dopamine available, the brain struggles to initiate movement, which results in clinical features we call parkinsonism. Parkinsonism is a clinical syndrome that includes bradykinesia, rigidity, tremor, and postural instability.

Key Takeaways

Parkinson's is a progressive movement disorder caused by degeneration of dopamine-producing neurons in the substantia nigra, specifically in the pars compacta, which leads to resting tremor, rigidity, problems initiating movement, and postural instability, and for which therapy primarily focuses on increasing brain dopamine.

There is no cure for this condition, but medications can increase dopamine levels in the brain and control tremors. There is also deep-brain stimulation, which involves an implantable device that directly sends electrical signals to the basal ganglia that counteract the abnormal signaling in Parkinson's.

Sources

  1. "Robbins & Kumar Basic Pathology. Available from: ClinicalKey Student, (11th Edition). (pg 754-755) " Elsevier Limited (UK) (2022)
  2. "Robbins & Cotran Pathologic Basis of Disease. Available from: ClinicalKey Student, (10th Edition). (pg-1282-1284)" Elsevier Health Sciences (US) (2020.)
  3. "Crush Step 1 E-Book. Available from: ClinicalKey Student, (3rd Edition).(pg-523-524) " Elsevier Limited (UK) (2023)
  4. "Conn's Current Therapy 2025. Available from: ClinicalKey Student, Page 820-826 " Elsevier Limited (UK) (2024 )